Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.63 |
| ▸ | PI4KA | P42356 | 3/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38913 | 0.98 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL67131 | 0.95 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5033136 | 0.88 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL20445820 | 0.87 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5015473 | 0.87 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL14037129 | 0.87 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11222112 | 0.86 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5017547 | 0.86 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL19553487 | 0.86 | ADORA2A (0.91) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL8972244 | 0.86 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADCY5PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318878-A1 | Antibacterial Agents | RANBAXY LABORATRIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
| EP-1812455-A2 | ERYTHROMYCIN A DERIVATIVES AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006035301-A2 | ERYTHROMYCIN A DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
| US-5614614-A | ANTIBIOTICS, CHEMICAL INTERMEDIATES | ROUSSEL UCLAF (FR) | 1997-03-25 | — | — | US | disclosed |
| US-5527780-A | BACTERICIDES | ROUSSEL UCLAF (FR) | 1996-06-18 | — | — | US | disclosed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318878-A1 | Antibacterial Agents | MLX, MGAM, CAT | ADORA2A 4033/4885ADORA1 4188/4885ADORA2B 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.